{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:06:23Z","timestamp":1787018783587,"version":"build-2736575974"},"reference-count":13,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>This case report evaluated the efficacy and safety of dupilumab, a monoclonal antibody targeting interleukin-4 and interleukin-13, in a patient with atopic dermatitis (AD) and a history of metastatic renal cancer. Over 20 months of follow-up, the patient experienced significant improvement in AD symptoms without any recurrence of cancer. In addition to not stimulating carcinogenesis, dupilumab might synergistically inhibit tumor-induced immunosuppression, thereby potentially preventing tumor progression. This case suggests that dupilumab could be a viable treatment option for patients with AD and a history of solid neoplasms, filling a critical gap in current therapeutic approaches. Current evidence indicates that dupilumab does not promote cancer progression, but further research is necessary to confirm its long-term safety in this population. To establish robust scientific evidence and develop precise clinical guidelines, future studies should be randomized, controlled, and large-scale. This will help provide a definitive understanding of the safety and efficacy of dupilumab in patients with a history of cancer and inform clinical practice. In summary, although the initial findings are promising, comprehensive research is essential to ensure the optimal management of AD in patients with a history of malignancies.<\/jats:p>","DOI":"10.1177\/03000605241297551","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T05:17:37Z","timestamp":1732252657000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of dupilumab in a patient with metastatic clear cell renal cell carcinoma"],"prefix":"10.1177","volume":"52","author":[{"given":"C\u00e9sar","family":"Ferreira","sequence":"first","affiliation":[{"name":"Department of Dermatology, Centro Hospitalar Universit\u00e1rio do Porto, Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eg\u00eddio","family":"Freitas","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Centro Hospitalar Universit\u00e1rio do Porto, Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Centro Hospitalar Universit\u00e1rio do Porto, Porto, Portugal"},{"name":"Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar, University of Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"key":"bibr1-03000605241297551","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.12.022"},{"key":"bibr2-03000605241297551","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12031191"},{"key":"bibr3-03000605241297551","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.09.002"},{"key":"bibr4-03000605241297551","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3201"},{"key":"bibr5-03000605241297551","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18922"},{"key":"bibr6-03000605241297551","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.051"},{"key":"bibr7-03000605241297551","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2021-9-5"},{"key":"bibr8-03000605241297551","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-022-02362-y"},{"key":"bibr9-03000605241297551","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17264"},{"key":"bibr10-03000605241297551","doi-asserted-by":"publisher","DOI":"10.1111\/head.12246"},{"key":"bibr11-03000605241297551","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19873"},{"key":"bibr12-03000605241297551","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06797-9"},{"key":"bibr13-03000605241297551","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16388"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605241297551","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03000605241297551","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605241297551","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:49:09Z","timestamp":1777459749000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03000605241297551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1177\/03000605241297551"],"URL":"https:\/\/doi.org\/10.1177\/03000605241297551","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"value":"0300-0605","type":"print"},{"value":"1473-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"article-number":"03000605241297551"}}